Hereditary Hemorrhagic Telangiectasia News and Research

RSS

Researchers identify substantial lack of racial and ethnic data in studies of rare genetic disorder

In a review of published research papers, investigators from the Johns Hopkins Medicine Hereditary Hemorrhagic Telangiectasia Center have identified a substantial lack of racial and ethnic data that may be negatively impacting the treatment and diagnosis of this rare disorder in diverse patients.

11 Jul 2022

New evidence-based clinical practice guideline for nosebleed published

The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery.

7 Jan 2020

ACG publishes new guideline on disorders of hepatic and mesenteric circulation

The American College of Gastroenterology is pleased to announce the publication of a new ACG Clinical Guideline on Disorders of Hepatic and Mesenteric Circulation, which was published online today in The American Journal of Gastroenterology.

7 Jan 2020

Research leads to new potential treatment for Hereditary Hemorrhagic Telangiectasia

The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute - Catalan Institute of Oncology - University of Barcelona, together with Dr. Antoni Riera-Mestre, has led to a new potential treatment for Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Syndrome, a rare disease that affects blood vessels and had no described treatment.

26 Apr 2018

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings

29 Jan 2018

Tulane professor wins Department of Defense grant for research into arteriovenous malformations

Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.

14 Nov 2017

NIH awards $15 million to develop 3D microphysiological system platforms that model human disease

More than 60 percent of investigational drugs fail in human clinical trials due to a lack of effectiveness, despite promising pre-clinical studies using cell and animal research models.

13 Sep 2017

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.

6 Sep 2016

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia.

17 Mar 2015

Blood vessels play an important role in preventing spread of tumour cells

A lack of the protein endoglin in the blood vessels of tumour-bearing mice enables the spread of daughter tumours, according to researchers at Karolinska Institutet and Lund University in Sweden in a study published in the scientific periodical The Journal of Experimental Medicine. Given that the tumour vasculature constitutes an important barrier to the spread of cancer cells, the team suggests that drugs should be developed to strengthen the blood vessels' protective function.

12 Feb 2013

Bevacizumab drug improves cardiac output in patients with HHT

In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.

6 Mar 2012

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009